

Newsletter



Intoinworld Co., Ltd., a people-focused company.
"From people to people, connecting the value of clinical research."

Intoinworld Co., Ltd. strives to be a bridge of trust between patients, investigators, and sponsors, ensuring that the value of medical innovation is safely delivered to people. Founded in 2015, we are a contract research organization (CRO) that conducts diverse clinical studies across pharmaceuticals, biotechnology, medical devices, investigator-initiated trials (IITs) and observational studies, guided by a people-centered mindset.



'MFDS rolls out 60 safety initiatives to boost biopharma, rare disease care

The MFDS is implementing regulatory reforms to boost Korea's biopharma industry and improve access to rare disease treatments. Key measures include integrating patient experience data into drug reviews, establishing certification standards for biopharmaceutical raw materials, and issuing new guidelines for cell and gene therapies. The initiative also aims to stabilize essential medicine supply and expand stakeholder participation, strengthening both regulatory efficiency and global competitiveness.

'Korea approves clinical study of NK cell therapy for recurrent glioblastoma

A clinical study in Korea will test an autologous NK cell therapy for recurrent glioblastoma, a highly aggressive brain cancer with high relapse rates. Using patients' own immune cells, the therapy aims to improve progression-free survival and address the lack of effective post-relapse treatments.



'Drug discovery AI moves beyond hype to an R&D productivity test

AI in drug discovery is shifting from hype to practical use. Rather than replacing the entire process, it now focuses on solving key bottlenecks like target identification and clinical optimization. The real challenge is integrating AI effectively across the full R&D workflow.



Newsletter





'The next step after AI drug development is 'autonomous laboratories'... Infrastructure needs to be built

Self-Driving Laboratories (SDLs) are emerging as a key solution to improve AI-driven drug development. By combining AI with automated experiments, SDLs enable continuous cycles of prediction, testing, and learning, reducing time, cost, and experimental inefficiencies.

'Breast Cancer Ranks No. 1 in Global Anticancer Drug Market Revenue... Projected to Reach \$218 Billion by 2035

The global breast cancer treatment market is expected to reach \$218 billion by 2035, driven by strong growth in CDK4/6 inhibitors, immunotherapies, and an active pipeline with over 400 ongoing projects.



'First Domestic CAR-T 'Limcato' Establishes Reimbursement Criteria... Clears Cancer Drug Review Board's Threshold

Curocell's Limcato, the first domestically developed CAR-T therapy, has established reimbursement criteria after additional clinical evidence publication, marking a key step toward national health insurance listing in Korea.